List all clinical trials by discovery date. Accepts regular expressions in search.

GET /trials/?page=2
HTTP 200 OK
Allow: GET, POST, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept

{
    "count": 728,
    "next": "http://api.gregory-ms.com/trials/?page=3",
    "previous": "http://api.gregory-ms.com/trials/",
    "results": [
        {
            "trial_id": 383885,
            "title": "The Effects of Action Observation Therapy (AOT) on Balance and Gait in Patients With Multiple Sclerosis.",
            "summary": "<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: Action Observation Therapy<br /><b>Sponsor</b>:    Shiraz University of Medical Sciences<br /><b>Not yet recruiting</b>",
            "published_date": "2022-09-16T12:00:00Z",
            "discovery_date": "2022-09-16T14:10:13.573490Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT05543213?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 383310,
            "title": "The Effect of Reflexology and Pelvic Floor Muscle Exercises (Kegel) on Urinary Incontinence in MS Patients",
            "summary": "<b>Conditions</b>:    Multiple Sclerosis;   Reflexology;   Urinary Incontinence<br /><b>Intervention</b>:    Other: Reflexology and kegel exercises<br /><b>Sponsor</b>:    Ondokuz Mayıs University<br /><b>Recruiting</b>",
            "published_date": "2022-09-15T12:00:00Z",
            "discovery_date": "2022-09-15T10:45:15.934300Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT05541965?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 382897,
            "title": "Vancomycin Study in Multiple Sclerosis (MS)",
            "summary": "<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Vancomycin;   Drug: Placebo<br /><b>Sponsors</b>:    Icahn School of Medicine at Mount Sinai;   Doris Duke Charitable Foundation<br /><b>Not yet recruiting</b>",
            "published_date": "2022-09-14T12:00:00Z",
            "discovery_date": "2022-09-14T15:35:19.909417Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT05539729?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 380247,
            "title": "DECISIve - DiagnosE Using the Central veIn SIgn v1.0",
            "summary": "<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Diagnostic Test: Lumbar puncture;   Diagnostic Test: MRI<br /><b>Sponsor</b>:    Nottingham University Hospitals NHS Trust<br /><b>Active, not recruiting</b>",
            "published_date": "2022-09-09T12:00:00Z",
            "discovery_date": "2022-09-09T15:00:11.488291Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT05533905?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 379693,
            "title": "A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)",
            "summary": "<b>Condition</b>:    Multiple Sclerosis, Relapsing-Remitting<br /><b>Intervention</b>:    Drug: Natalizumab<br /><b>Sponsor</b>:    Biogen<br /><b>Not yet recruiting</b>",
            "published_date": "2022-09-08T12:00:00Z",
            "discovery_date": "2022-09-08T13:20:18.373479Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT05532163?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 379691,
            "title": "Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis",
            "summary": "<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Biological: Allogeneic umbilical cord mesenchymal stem cells;   Biological: Control group<br /><b>Sponsor</b>:    Ever Supreme Bio Technology Co., Ltd.<br /><b>Not yet recruiting</b>",
            "published_date": "2022-09-08T12:00:00Z",
            "discovery_date": "2022-09-08T13:20:18.369338Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT05532943?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 379244,
            "title": "High Intensity Interval Gait Training in Multiple Sclerosis",
            "summary": "<b>Condition</b>:    Multiple Sclerosis,Gait, Exercise<br /><b>Interventions</b>:    Behavioral: Moderate paced continuous gait training;   Behavioral: High Intensity Interval gait training<br /><b>Sponsor</b>:    City University of New York<br /><b>Recruiting</b>",
            "published_date": "2022-09-07T12:00:00Z",
            "discovery_date": "2022-09-07T14:40:13.228894Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT05529498?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 378779,
            "title": "Risk Perception in Multiple Sclerosis",
            "summary": "<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: High Efficacy Therapy (HET);   Other: Non High Efficacy Therapy (Non-HET)<br /><b>Sponsor</b>:    Novartis Pharmaceuticals<br /><b>Completed</b>",
            "published_date": "2022-09-05T12:00:00Z",
            "discovery_date": "2022-09-06T14:55:13.287943Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT05528666?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 376552,
            "title": "Effects of Dual-Task Training in People With Multiple Sclerosis",
            "summary": "<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Other: Dual-Task Training;   Other: Home Exercise Program<br /><b>Sponsor</b>:    Ege University<br /><b>Not yet recruiting</b>",
            "published_date": "2022-09-02T12:00:00Z",
            "discovery_date": "2022-09-02T15:55:22.461574Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT05526287?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 375907,
            "title": "A 2-year Prospective Study to Assess Health-related Quality of Life in Subjects with Highly-Active Relapsing Multiple Sclerosis Treated with Mavenclad®",
            "summary": "<p>EudraCT Number: 2017-002632-17<br />Sponsor Protocol Number: MS700568_0021<br />Sponsor Name: Merck KGaA<br />Start Date: 2018-01-30<br />Medical condition: Relapsing multiple sclerosis<br />Disease: <br />Version: 20.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/LT\">LT</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/HU\">HU</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/AT\">AT</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/SE\">SE</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/ES\">ES</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/CZ\">CZ</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/DK\">DK</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/BE\">BE</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/FI\">FI</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/GB\">GB</a> (GB - no longer in EU/EEA), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/FR\">FR</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/NL\">NL</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/SK\">SK</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/PT\">PT</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/GR\">GR</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002632-17/IT\">IT</a> (Ongoing)</p>",
            "published_date": null,
            "discovery_date": "2022-09-01T12:35:18.990114Z",
            "link": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-002632-17",
            "source": null,
            "relevant": null
        }
    ]
}